FGF2 and breast carcinoma: Recent studies indicate that elevated levels of cytosolic low molecular weight FGF-2 (18 kDa) successfully activated intracellular ERK1/2, which reduced breast cancer cell (MCF-7) migration and proliferation [32] The recombinant FGF-2 (both 18 kDa and 23 kDa) intracellular delivery inhibited MCF-7 proliferation and induced downregulation of B-cell lymphoma 2 (Bcl-2) and increased levels of Bax, without involving receptor-mediated signaling [32].